We report a novel case of a transgender woman who experienced excess mucosal secretion leading to symptomatic skin irritation after her colonic vaginoplasty successfully treated with glycopyrrolate.
Methods:
This is a case report of a 47-year-old transgender woman with symptomatic excess mucosal secretion and skin irritation from colonic vaginoplasty, and we describe her treatment course and responses. Patient consent was obtained for publication.
Results:
The patient's chronic neovaginal discharge improved with glycopyrrolate.
Conclusions:
Anticholinergic drugs may be helpful in treating patients who experience chronic neovaginal discharge following colonic vaginoplasty.
Get full access to this article
View all access options for this article.
References
1.
HorbachSE, BoumanMB, SmitJM, et al.Outcome of vaginoplasty in male-to-female transgenders: a systematic review of surgical techniques. J Sex Med. 2015; 12:1499–1512.
2.
van der SluisWB, PavanN, LiguoriG, et al.Ileal vaginoplasty as vaginal reconstruction in transgender women and patients with disorders of sex development: an international, multicentre, retrospective study on surgical characteristics and outcomes. BJU Int. 2018; 121:952–958.
3.
SalgadoCJ, NugentA, KuhnJ, et al.Primary sigmoid vaginoplasty in transwomen: technique and outcomes. Biomed Res Int. 2018; 2018:4907208.
4.
GarciaMM, ShenW, ZhuR, et al.Use of right colon vaginoplasty in gender affirming surgery: proposed advantages, review of technique, and outcomes. Surg Endosc. 2021; 35:5643–5654.
5.
Kwun KimS, Hoon ParkJ, Cheol LeeK, et al.Long-term results in patients after rectosigmoid vaginoplasty. Plast Reconstr Surg. 2003; 112:143–151.
6.
van der SluisWB, de HasethKB, ElferingL, et al.Neovaginal discharge in transgender women after vaginoplasty: a diagnostic and treatment algorithm. Int J Transgend Health. 2020; 21:367–372.
7.
BustosSS, BustosVP, MascaroA, et al.Complications and patient-reported outcomes in transfemale vaginoplasty: an updated systematic review and meta-analysis. Plast Reconstr Surg Glob Open. 2021; 9:e3510.
8.
GerretsenP, PollockBG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011; 10:751–765.
9.
LiebermanJA, 3rd. Managing anticholinergic side effects [published correction appears in Prim Care Companion J Clin Psychiatry. 2012;14:PCC.12lcx01362]. Prim Care Companion J Clin Psychiatry. 2004; 6:20–23.
10.
GlaserDA, HebertAA, NastA, et al.Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019; 80:128.e2–138.e2.
